OPIATE OVERDOSE RESPONSE ACT AMENDMENTS
2017 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Carol Spackman Moss
Senate Sponsor: Brian E. Shiozawa
LONG TITLE
General Description:
This bill amends civil liability in the Opiate Overdose Response Act.
Highlighted Provisions:
This bill:
• identifies the persons who are not civilly liable when administering an opiate
antagonist under certain circumstances;
 permits an overdose outreach provider to furnish an opiate antagonist to another
overdose outreach provider; and
makes technical changes.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
26-55-102, as last amended by Laws of Utah 2016, Chapters 127, 202, 207, and 208
26-55-104, as last amended by Laws of Utah 2016, Chapters 202, 207, 208 and last
amended by Coordination Clause, Laws of Utah 2016, Chapter 202
26-55-106, as enacted by Laws of Utah 2016, Chapter 207 and last amended by
Coordination Clause, Laws of Utah 2016, Chapter 202
58-17b-501, as last amended by Laws of Utah 2013, Chapter 262

54

55

Be it enacted by the Legislature of the state of Utah:
Section 1. Section 26-55-102 is amended to read:
26-55-102. Definitions.
As used in this chapter:
(1) "Controlled substance" means the same as that term is defined in Title 58, Chapter
37, Utah Controlled Substances Act.
(2) "Dispense" means the same as that term is defined in Section 58-17b-102.
(3) "Health care facility" means a hospital, a hospice inpatient residence, a nursing
facility, a dialysis treatment facility, an assisted living residence, an entity that provides home-
and community-based services, a hospice or home health care agency, or another facility that
provides or contracts to provide health care services, which facility is licensed under Chapter
21, Health Care Facility Licensing and Inspection Act.
(4) "Health care provider" means:
(a) a physician, as defined in Section 58-67-102;
(b) an advanced practice registered nurse, as defined in Section 58-31b-102;
(c) a physician assistant, as defined in Section 58-70a-102; or
(d) an individual licensed to engage in the practice of dentistry, as defined in Section
58-69-102.
(5) "Increased risk" means risk exceeding the risk typically experienced by an
individual who is not using, and is not likely to use, an opiate.
(6) "Local health department" means:
(a) a local health department, as defined in Section 26A-1-102; or
(b) a multicounty local health department, as defined in Section 26A-1-102.
(7) "Opiate" means the same as that term is defined in Section 58-37-2.

(8) "Opiate antagonist" means naloxone hydrochloride or any similarly acting drug that

is not a controlled substance and that is approved by the federal Food and Drug Administration

56 for the diagnosis or treatment of an opiate-related drug overdose. 57 (9) "Opiate-related drug overdose event" means an acute condition, including a decreased level of consciousness or respiratory depression resulting from the consumption or 58 59 use of a controlled substance, or another substance with which a controlled substance was 60 combined, and that a person would reasonably believe to require medical assistance. 61 (10) "Overdose outreach provider" means: 62 (a) a law enforcement agency; 63 (b) a fire department; 64 (c) an emergency medical service provider, as defined in Section 26-8a-102; (d) emergency medical service personnel, as defined in Section 26-8a-102; 65 66 (e) an organization providing treatment or recovery services for drug or alcohol use; 67 (f) an organization providing support services for an individual, or a family of an individual, with a substance use disorder: 68 (g) an organization providing substance use or mental health services under contract 69 70 with a local substance abuse authority, as defined in Section 62A-15-102, or a local mental 71 health authority, as defined in Section 62A-15-102; 72 (h) an organization providing services to the homeless; (i) a local health department; [or] 73 74 (i) an individual licensed to practice pharmacy under Title 58, Chapter 17b, Pharmacy 75 Practice Act; or 76 $[\frac{1}{2}]$ (k) an individual. (11) "Patient counseling" means the same as that term is defined in Section 77 78 58-17b-102. 79 (12) "Pharmacist" means the same as that term is defined in Section 58-17b-102. 80 (13) "Pharmacy intern" means the same as that term is defined in Section 58-17b-102. 81 (14) "Prescribe" means the same as that term is defined in Section 58-17b-102. 82 Section 2. Section **26-55-104** is amended to read:

83	26-55-104. Prescribing, dispensing, and administering an opiate antagonist
84	Immunity from liability.
85	(1) (a) (i) For purposes of Subsection (1)(a)(ii), "a person other than a health care
86	facility or health care provider" includes the following, regardless of whether the person has
87	received funds from the department through the Opiate Overdose Outreach Pilot Program
88	created in Section 26-55-107:
89	(A) a person described in Subsections 26-55-107(1)(a)(i)(A) through (1)(a)(i)(F); or
90	(B) an organization, defined by department rule made under Subsection
91	26-55-107(7)(e), that is in a position to assist an individual who is at increased risk of
92	experiencing an opiate-related drug overdose event.
93	(ii) Except as provided in Subsection (1)(b), [a person, including an overdose outreach
94	provider, but not including a health care facility or health care provider, that] the following
95	persons are not liable for any civil damages for acts or omissions made as a result of
96	administering an opiate antagonist when the person acts in good faith to administer [an] the
97	opiate antagonist to an individual whom the person believes to be experiencing an
98	opiate-related drug overdose event [is not liable for any civil damages for acts or omissions
99	made as a result of administering the opiate antagonist.]:
100	(A) an overdose outreach provider; or
101	(B) a person other than a health care facility or health care provider.
102	(b) A health care provider:
103	(i) [does] is not [have immunity] immune from liability under Subsection (1)(a) when
104	the health care provider is acting within the scope of the health care provider's responsibilities
105	or duty of care; and
106	(ii) [does have immunity] is immune from liability under Subsection (1)(a) if the health
107	care provider is under no legal duty to respond and otherwise complies with Subsection (1)(a).
108	(2) Notwithstanding Sections 58-1-501, 58-17b-501, and 58-17b-502, a health care
109	provider who is licensed to prescribe an opiate antagonist may prescribe, including by a

110 standing prescription drug order issued in accordance with Subsection 26-55-105(2), or 111 dispense an opiate antagonist: 112 (a) (i) to an individual who is at increased risk of experiencing an opiate-related drug 113 overdose event; 114 (ii) for an individual described in Subsection (2)(a)(i), to a family member [of], friend 115 [of], or other person, including a person described in Subsections 26-55-107(1)(a)(i)(A) 116 through (1)(a)(i)(F), that is in a position to assist [an] the individual [who is at increased risk of 117 experiencing an opiate-related drug overdose event]; or 118 (iii) to an overdose outreach provider for: 119 (A) furnishing the opiate antagonist to an individual [who is at increased risk of 120 experiencing an opiate-related drug overdose event, or to a family member of, friend of, or 121 other individual who is in a position to assist an individual who is at increased risk of 122 experiencing an opiate-related drug overdose event described in Subsection (2)(a)(i) or (ii), as 123 provided in Section 26-55-106; or 124 (B) administering to an individual experiencing an opiate-related drug overdose event; 125 (b) without a prescriber-patient relationship; and 126 (c) without liability for any civil damages for acts or omissions made as a result of 127 prescribing or dispensing the opiate antagonist in good faith. (3) A health care provider who dispenses an opiate antagonist to an individual or an 128 129 overdose outreach provider under Subsection (2)(a) shall provide education to the individual or 130 overdose provider that includes written instruction on how to: 131 (a) recognize an opiate-related drug overdose event; and 132 (b) respond appropriately to an opiate-related drug overdose event, including how to: 133 (i) administer an opiate antagonist; and 134 (ii) ensure that an individual to whom an opiate antagonist has been administered 135 receives, as soon as possible, additional medical care and a medical evaluation. 136 Section 3. Section **26-55-106** is amended to read:

Enrolled Copy

13/	26-55-106. Overdose outreach providers.
138	Notwithstanding Sections 58-1-501, 58-17b-501, and 58-17b-502:
139	(1) an overdose outreach provider may:
140	(a) obtain an opiate antagonist dispensed on prescription by:
141	(i) a health care provider, in accordance with Subsections 26-55-104(2) and (3); or
142	(ii) a pharmacist or pharmacy intern, as otherwise authorized by Title 58, Chapter 17b,
143	Pharmacy Practice Act;
144	(b) store the opiate antagonist; and
145	(c) furnish the opiate antagonist:
146	(i) (A) to an individual who is at increased risk of experiencing an opiate-related drug
147	overdose event; or
148	(B) to a family member [of], friend [of], overdose outreach provider, or other
149	individual who is in a position to assist an individual who is at increased risk of experiencing
150	an opiate-related drug overdose event; and
151	(ii) without liability for any civil damages for acts or omissions made as a result of
152	furnishing the opiate antagonist in good faith; and
153	(2) when furnishing an opiate antagonist under Subsection (1), an overdose outreach
154	provider:
155	(a) shall also furnish to the recipient of the opiate antagonist:
156	(i) the written instruction under Subsection 26-55-104(3) received by the overdose
157	outreach provider from the health care provider at the time the opiate antagonist was dispensed
158	to the overdose outreach provider; or
159	(ii) if the opiate antagonist was dispensed to the overdose outreach provider by a
160	pharmacist or pharmacy intern, any written patient counseling under Section 58-17b-613
161	received by the overdose outreach provider at the time of dispensing; and
162	(b) may provide additional instruction on how to recognize and respond appropriately
163	to an opiate-related drug overdose event.

164 Section 4. Section **58-17b-501** is amended to read: 165 58-17b-501. Unlawful conduct. 166 "Unlawful conduct" includes: 167 (1) knowingly preventing or refusing to permit an authorized agent of the division to 168 conduct an inspection pursuant to Section 58-17b-103; 169 (2) failing to deliver the license, permit, or certificate to the division upon demand, if it 170 has been revoked, suspended, or refused: 171 (3) (a) using the title "pharmacist," "druggist," "pharmacy intern," "pharmacy 172 technician," or a term having similar meaning, except by a person licensed as a pharmacist, 173 pharmacy intern, or pharmacy technician; or 174 (b) conducting or transacting business under a name that contains, as part of that name, the words "drugstore," "pharmacy," "drugs," "medicine store," "medicines," "drug shop," 175 "apothecary," "prescriptions," or a term having a similar meaning, or in any manner 176 177 advertising, otherwise describing, or referring to the place of the conducted business or 178 profession, unless the place is a pharmacy issued a license by the division, except an 179 establishment selling nonprescription drugs and supplies may display signs bearing the words "packaged drugs," "drug sundries," or "nonprescription drugs," and is not considered to be a 180 181 pharmacy or drugstore by reason of the display; 182 (4) buying, selling, causing to be sold, or offering for sale, a drug or device that bears, 183 or the package bears or originally did bear, the inscription "sample," "not for resale," "for 184 investigational or experimental use only," or other similar words, except when a cost is 185 incurred in the bona fide acquisition of an investigational or experimental drug; 186 (5) using to a person's own advantages or revealing to anyone other than the division, 187 board, and its authorized representatives, or to the courts, when relevant to a judicial or 188 administrative proceeding under this chapter, information acquired under authority of this 189 chapter or concerning a method of process that is a trade secret;

(6) procuring or attempting to procure a drug or to have someone else procure or

190

Enrolled Copy

191	attempt to procure a drug:
192	(a) by fraud, deceit, misrepresentation, or subterfuge;
193	(b) by forgery or alteration of a prescription or a written order;
194	(c) by concealment of a material fact;
195	(d) by use of a false statement in a prescription, chart, order, or report; or
196	(e) by theft;
197	(7) filling, refilling, or advertising the filling or refilling of prescriptions for a
198	consumer or patient residing in this state if the person is not licensed:
199	(a) under this chapter; or
200	(b) in the state from which he is dispensing;
201	(8) requiring an employed pharmacist, pharmacy intern, pharmacy technician, or
202	authorized supportive personnel to engage in conduct in violation of this chapter;
203	(9) being in possession of a prescription drug for an unlawful purpose;
204	(10) dispensing a prescription drug to a person who does not have a prescription from a
205	practitioner, except as permitted under Title 26, Chapter 55, Opiate Overdose Response Act, or
206	to a person who the person dispensing the drug knows or should know is attempting to obtain
207	drugs by fraud or misrepresentation;
208	(11) selling, dispensing, distributing, or otherwise trafficking in prescription drugs
209	when not licensed to do so or when not exempted from licensure; and
210	(12) a person using a prescription drug or controlled substance that was not lawfully
211	prescribed for the person by a practitioner.